OyaGen is a Rochester, New York-based startup company that is focused on developing treatments for HIV. The company was founded in 2003 by Harold Smith, a professor of biochemistry and biophysics at the University of Rochester. OyaGen was founded on research conducted by Smith and Hui Zang, an HIV researcher at Thomas Jefferson University. OyaGen's research has focused on developing drug-based treatments for HIV and the company has three lead HIV drugs based upon editing enzymes in preclinical development. The company is exploring ways to prevent HIV from disabling the production of APOBEC3G (A3G), a naturally occurring editing enzyme that stops HIV from replicating. A3G combats HIV infection by interacting with and mutating the virus' RNA. The mutations genetically damage the virus protein and render HIV unable to replicate which halts the spread of the virus. In laboratory testing, OyaGen was able to use drug therapy to shield A3G from HIV, which allowed A3G to function normally and halt the spread of the virus. More information...
According to PR-model, oyageninc.com is ranked 1,886,159th in multilingual Wikipedia, in particular this website is ranked 1,046,574th in English Wikipedia.
The website is placed before cusquenos-ilustres.blogspot.com and after womenss.net in the BestRef global ranking of the most important sources of Wikipedia.
